NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
DiaMedica Therapeutics Inc (NASDAQ: DMAC)
DMAC Technical Analysis
3
As on 9th Jun 2023 DMAC STOCK Price closed @ 3.14 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.15 & Buy for SHORT-TERM with Stoploss of 3.06 we also expect STOCK to react on Following IMPORTANT LEVELS. |
DMACSTOCK Price
Open | 3.22 | Change | Price | % |
High | 3.45 | 1 Day | -0.09 | -2.79 |
Low | 3.14 | 1 Week | 0.39 | 14.18 |
Close | 3.14 | 1 Month | 1.61 | 105.23 |
Volume | 117977 | 1 Year | -0.41 | -11.55 |
52 Week High 3.88 | 52 Week Low 1.13 |
NASDAQ USA Most Active Stocks
TSLA | 244.40 | 4.06% |
TTOO | 0.07 | -12.50% |
SOFI | 8.18 | 0.74% |
FFIE | 0.33 | 6.45% |
PONO | 1.72 | 2.38% |
AMD | 124.92 | 3.20% |
IDEX | 0.06 | 0.00% |
NKLA | 0.70 | 14.75% |
AMZN | 123.43 | -0.66% |
AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
DMAC Daily Charts |
DMAC Intraday Charts |
Whats New @ Bazaartrend |
DMAC Free Analysis |
|
DMAC Important Levels Intraday
RESISTANCE | 3.74 |
RESISTANCE | 3.55 |
RESISTANCE | 3.43 |
RESISTANCE | 3.31 |
SUPPORT | 2.97 |
SUPPORT | 2.85 |
SUPPORT | 2.73 |
SUPPORT | 2.54 |
DMAC Forecast May 2024
4th UP Forecast | 6.45 |
3rd UP Forecast | 5.39 |
2nd UP Forecast | 4.73 |
1st UP Forecast | 4.08 |
1st DOWN Forecast | 2.2 |
2nd DOWN Forecast | 1.55 |
3rd DOWN Forecast | 0.89 |
4th DOWN Forecast | -0.17 |
DMAC Weekly Forecast
4th UP Forecast | 4.05 |
3rd UP Forecast | 3.76 |
2nd UP Forecast | 3.58 |
1st UP Forecast | 3.40 |
1st DOWN Forecast | 2.88 |
2nd DOWN Forecast | 2.70 |
3rd DOWN Forecast | 2.52 |
4th DOWN Forecast | 2.23 |
DMAC Forecast2024
4th UP Forecast | 8.57 |
3rd UP Forecast | 6.83 |
2nd UP Forecast | 5.75 |
1st UP Forecast | 4.68 |
1st DOWN Forecast | 1.6 |
2nd DOWN Forecast | 0.53 |
3rd DOWN Forecast | -0.55 |
4th DOWN Forecast | -2.29 |
DiaMedica Therapeutics Inc ( NASDAQ USA Symbol : DMAC )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
DMAC Other Details
Segment | EQ | |
Market Capital | 105756800.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
DMAC Address
DMAC Latest News
DMAC Business Profile
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Address: Two Carlson Parkway, Minneapolis, MN, United States, 55447
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service